Advertisements

Бактрим

Quick links to important sections

Бактрим

Selected form

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Бактрим

Property Description
Active ingredient Sulfamethoxazole and Trimethoprim
Form Tablet, Oral suspension, Solution for injection
Pharmacological class Antibacterial agent (Sulfonamide and DHFR inhibitor combination)
Common use Bacterial infections (e.g., respiratory, urinary tract)
Origin Synthetic

What Type of Medicine is Бактрим (Co-trimoxazole)?

Бактрим is a prescription-only medicine (Rx) classified as a broad-spectrum antibiotic and a synthetic anti-infective drug. Its chemical structure, a fixed-dose combination product, is formally recognized by the International Nonproprietary Name (INN) Co-trimoxazole. This medication belongs to the sulfonamide class and is recognized for its reliable efficacy across various infections.

Composition and Available Forms

Бактрим is composed of two distinct active ingredients: Sulfamethoxazole (SMX), a sulfonamide, and Trimethoprim (TMP), a dihydrofolate reductase inhibitor. This dual composition is a key feature, as the agents target the pathogen's metabolism sequentially. The drug is supplied in multiple pharmaceutical preparations, primarily the standard tablet form for oral use, an oral suspension often favored for pediatric patients, and a sterile solution for injection suitable for intravenous administration in hospital settings.

The General Purpose of This Combination Antibacterial Agent

The general purpose of this medication is to effectively fight off and eliminate widespread bacterial infections caused by susceptible microorganisms. The combination achieves a powerful synergistic effect by utilizing a process known as sequential blockade. By targeting two consecutive steps in the bacteria's critical folic acid pathway, the medication effectively halts the production of nucleic acids necessary for the growth and survival of the pathogen, which is a foundational way to suppress microbial proliferation in the body.

Regulatory References

  1. Co-trimoxazole Drug Information - MedlinePlus
  2. WHO Essential Medicines List - Co-trimoxazole Entry
  3. Sulfamethoxazole/Trimethoprim Mechanism of Action - NIH
  4. Trimethoprim Drug Information - MedlinePlus
  5. Dihydrofolate Reductase Inhibitor Definition - NCI
  6. Sulfonamides Drug Class - Merck Manuals
Advertisements

What side effects are possible with Бактрим?

Possible Side Effects and Safety Information

Бактрим (sulfamethoxazole and trimethoprim) carries a required regulatory Warning due to the potential for serious and sometimes fatal adverse reactions. These include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), as well as fulminant hepatic necrosis, agranulocytosis, and aplastic anemia.

Common and Serious Adverse Reactions

The most frequently reported side effects are generally gastrointestinal disturbances (such as nausea and vomiting) and allergic skin reactions (rash, hives).

Classification Examples of Clinically Significant Reactions
Serious / Potentially Fatal SJS, TEN, DRESS, Circulatory Shock, Hepatic Necrosis, Agranulocytosis, Hemophagocytic Lymphohistiocytosis (HLH), Acute Respiratory Failure.
Less Common / Hematologic Thrombocytopenia (low platelets), Leukopenia, Megaloblastic Anemia.

Safety Considerations for Specific Populations

  • Infants: The drug is generally contraindicated in infants less than two months of age due to the risk of toxicity.
  • Elderly Patients: Older adults are at a higher risk of experiencing severe side effects, including severe skin reactions, hyperkalemia (high potassium levels), and hematologic disorders. They are also more likely to have pre-existing renal or folate deficiency issues.
  • G6PD Deficiency: Use in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency may cause hemolytic anemia.
  • Pregnancy: Exposure during pregnancy has been associated with an increased risk of congenital malformations, notably neural tube defects.

Safety-related restrictions include a contraindication in patients with documented megaloblastic anemia due to folate deficiency, a history of drug-induced immune thrombocytopenia, or severe hepatic or renal impairment where monitoring is not possible. Discontinuation is required immediately if a skin rash or any sign of a serious reaction develops.

Advertisements

Overdose and Emergency Response

The official documentation for Бактрим (Co-trimoxazole) overdose identifies a spectrum of clinical manifestations and outlines specific emergency response actions.

Acute overdose presentations may include gastrointestinal disturbances such as nausea, vomiting, and loss of appetite, alongside neurological effects like headache, confusion, and fainting. Physiological signs that may accompany overdose include the presence of blood in the urine and the yellowing of the skin or eyes (jaundice). Severe outcomes listed in regulatory documents include the risk of seizures, loss of consciousness, and collapse. Furthermore, high-dose exposure necessitates monitoring for critical metabolic imbalances, particularly severe hyperkalemia (high serum potassium) and symptomatic hyponatremia (low serum sodium).

Immediate medical attention must be sought if an overdose is suspected. Official regulatory guidance specifies that individuals should immediately call emergency services if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened. While no specific antidote is known for acute overdose, management involves necessary symptomatic and supportive treatment. This includes ensuring adequate fluid intake and urinary output to mitigate the risk of crystalluria, and the close monitoring of serum electrolytes. For toxicity resulting from prolonged, high-dose exposure (chronic overdose), the administration of Leucovorin (folinic acid) is the required procedural step to counteract bone marrow effects. Elderly patients and those with renal impairment are noted to be at increased risk of serious side effects.

Advertisements

Therapeutic Uses of Бактрим

What Бактрим Treats: Main Uses and Benefits

Бактрим (Co-trimoxazole) is commonly used across distinct therapeutic domains where symptoms related to inflammatory or irritative states cause noticeable physiological strain, and it contributes to easing the overall symptom load associated with acute infection and its manifestations. Its applications span multiple major systems.


Easing Symptoms of Acute Infections

This supportive therapy is applied in addressing symptoms related to physical discomfort, such as the pronounced distress of dysuria (painful urination) linked to Urinary Tract Infections (UTIs), and the acute symptoms of diarrhea and stomach cramps that interfere with daily functioning in conditions like shigellosis or traveler's diarrhea. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as Acute Exacerbations of Chronic Bronchitis and the bacterial causes of acute otitis media (middle ear infection).

Supportive Therapy for High-Risk Episodes

Бактрим is relevant in conditions marked by increased physiological stress, such as Pneumocystis Jirovecii Pneumonia (PJP). It is used for managing symptoms that interfere with daily functioning, like persistent cough and rapid, labored breathing, offering symptomatic relief that helps patients cope more steadily with difficult, high-risk episodes and assists with maintaining functional stability.


Quick Fact: Relief for Systemic and Localized Discomfort

Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Бактрим (Co-trimoxazole) is defined by strict regulatory categories focusing on patient health and age.

Category Eligibility Status (Official)
Allowed Age Adults and pediatric patients 2 months of age and older.
Contraindicated Known allergy to the active ingredients; marked hepatic damage; severe renal insufficiency (CrCl less than 15 mL/min); megaloblastic anemia due to folate deficiency; infants less than 2 months; and patients taking dofetilide.
Restricted Use Renal impairment (CrCl 15–30 mL/min) requires a reduced dosage. Use in older adults requires caution due to an elevated risk of severe adverse reactions.
Pregnancy and Lactation Eligibility Status Status Official Wording
Pregnancy Restricted; generally avoided during the first trimester and near term due to potential fetal risk.
Lactation Not recommended, especially when breastfeeding infants who are premature, jaundiced, or G6PD-deficient.

Official regulatory criteria strictly define who can use the medicine, classifying use based primarily on the patient's age, metabolic health (e.g., folate status, porphyria), and the functional status of the kidneys and liver. These rules determine absolute prohibition or necessary risk mitigation for specific populations.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Co-trimoxazole (Sulfamethoxazole/Trimethoprim) is officially documented by regulatory agencies and includes strict prohibitions and substances requiring mandatory monitoring due to altered drug exposure or additive effects.


Formal Prohibitions and Restrictions

  • Dofetilide: Co-administration is contraindicated by the FDA due to the risk of doubling Dofetilide plasma levels, which can lead to severe cardiac events. This effect is attributed to the inhibition of renal tubular secretion.
  • Methenamine: This combination is generally not recommended due to the potential for crystalluria.
  • Oral Typhoid Vaccine (Live): The effectiveness of this live vaccine may be reduced. Regulatory guidance advises a separation of at least three days between the last dose of the antibiotic and the vaccine administration.

Clinically Significant Interactions

Interacting Substance Documented Outcome (Label-Based)
Warfarin (Anticoagulants) Increased anticoagulant effect and prolonged INR, often requiring close monitoring.
Phenytoin (Anticonvulsant) Increased serum concentrations and prolonged half-life due to inhibited clearance.
ACE Inhibitors / ARBs Increased risk of hyperkalemia (high potassium levels) due to an additive potassium-sparing effect.
Digoxin (Cardiac Glycoside) May increase plasma levels, with this risk being notably higher in elderly patients.
Oral Hypoglycemics Potentiation of hypoglycemic effects (low blood sugar), requiring blood glucose monitoring.

Population-Specific Notes

Regulatory documents emphasize that the risk of thrombocytopenia with purpura is increased when co-administered with thiazide diuretics in elderly patients. Patients with suspected folate depletion are also at higher risk for severe hematological toxicity.

Advertisements

Mechanism of Action

Бактрим (Co-trimoxazole) functions via sequential blockade, a dual mechanism targeting the microbial folic acid synthesis pathway. The Sulfamethoxazole (SMX) component acts as a competitive inhibitor of the enzyme Dihydropteroate synthase (DHPS). Simultaneously, the Trimethoprim (TMP) component selectively blocks Dihydrofolate reductase (DHFR), an enzyme essential for converting dihydrofolate into the active co-factor, tetrahydrofolate.

This coordinated inhibition creates a metabolic bottleneck, starving the microbe of the necessary precursors (purines and thymidylate) required for DNA and RNA synthesis. The resulting failure to replicate leads to a bactericidal physiological effect—the collapse and termination of the pathogen's growth cycle—in contrast to the typically bacteriostatic effect of the single components. A secondary mechanism involves the TMP component's non-selective inhibition of the Epithelial Sodium Channel (ENaC) in the renal tubule, which modulates the potassium excretion process.

Advertisements

Dosage and Administration Information

Бактрим (Co-trimoxazole) is administered through two methods: orally, using either the tablet or oral suspension forms, or by intravenous (IV) infusion for patients who require parenteral administration.

Administration Routes and Forms

Route Forms
Oral Tablet (Standard or Double Strength), Oral Suspension
Intravenous Solution for Injection (must be diluted)

Standard adult dosing for general acute infections typically involves 160 mg of Trimethoprim (TMP) and 800 mg of Sulfamethoxazole (SMX) administered twice daily (every 12 hours). For high-intensity treatment regimens, such as for Pneumocystis jirovecii Pneumonia (PJP), the dose is weight-based and may be administered more frequently, such as every 6 to 8 hours.

The oral forms should be taken with a full glass of water, preferably alongside some food or drink, to ensure adequate hydration and optimize intake. Treatment duration is specific to the condition, ranging from short courses of 3 to 5 days to extended regimens of **14 to 21 days for severe uses.

Procedural Conditions and Adjustments

Dosing requires modification for certain populations. For pediatric patients over two months of age, the dosage is weight-based. Adults with moderate renal impairment (creatinine clearance 15 to 30 mL/min) must receive half the standard dose. Furthermore, the IV solution must be diluted prior to use and must be administered via slow infusion over 60 to 90 minutes; it is not approved for rapid injection or intramuscular delivery. If a dose is missed, it is suggested to take it if less than six hours past the scheduled time; otherwise, the dose should be omitted.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

This section summarizes research and clinical studies related to the use and effectiveness of trimethoprim/sulfamethoxazole (co-trimoxazole), commonly known by the brand name Bactrim or Бактрим.


Evaluation in Infectious Conditions

Clinical research has historically focused on the utility of this combination antibiotic in treating a variety of infections, primarily including urinary tract infections (UTIs), acute exacerbations of chronic bronchitis, and Pneumocystis jirovecii pneumonia (PJP).

  • Urinary Tract Infections (UTIs): Studies have evaluated the efficacy of co-trimoxazole, particularly in cases of uncomplicated UTIs. Data suggests that while effective, susceptibility patterns can vary geographically and over time due to bacterial resistance. Research continues to track these resistance trends to inform clinical guidelines.

  • Pneumocystis Jirovecii Pneumonia (PJP): Co-trimoxazole remains the standard of care, both for the treatment and prophylaxis of PJP, especially in immunocompromised patient populations. Clinical trials have established its role in reducing the incidence and mortality associated with this specific fungal infection.

Secondary Uses and Safety Profile

Research has also explored the compound's application in skin and soft tissue infections, though its usage is often reserved for specific scenarios or when other agents are not suitable.

Ongoing clinical monitoring and pharmacovigilance studies consistently review the safety profile of co-trimoxazole. These studies track potential adverse reactions, including dermatological issues, hematological effects, and interactions, particularly in elderly populations or those with underlying kidney impairment. Evidence-based reviews emphasize that dosage adjustments are often necessary in patients with reduced renal function to maintain safety, an aspect routinely addressed in study protocols and clinical practice guidelines.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Бактрим (FAQ)

Q: How quickly does Бактрим start to work for a typical infection?

A: Official regulatory documents indicate that peak concentrations of the active components generally occur relatively quickly, typically within one to four hours after the medication is administered. This indicates the time when the medication reaches its maximum concentration, but the therapeutic response, or feeling of improvement, may require more time.

Q: Why do official documents mention potential kidney problems with Бактрим?

A: Regulatory information notes that the drug is primarily eliminated from the body by the kidneys, requiring dose adjustments for individuals with impaired kidney function. In situations involving high doses, maintaining adequate fluid intake is important because of the potential for a condition called crystalluria, where crystals form in the urine.

Q: Is it safe to use Бактрим if I have severe anemia?

A: According to official regulatory labeling, this medicine is contraindicated (should not be used) in patients who have documented megaloblastic anemia that is caused by a folate deficiency. Regulatory information defines this specific medical situation as a contraindication due to established safety risks.

Q: Is there a link between Бактрим and an increased risk of kidney stones?

A: While regulatory sources do not typically focus on kidney stones directly, they highlight that maintaining fluid intake is important during treatment. This is to reduce the risk of crystalluria, which is the formation of crystals in the urine.

Q: Is the dosage for children based only on weight, or are there other factors?

A: Official dosing guidelines state that pediatric dosage is primarily calculated based on the child's body weight or their Body Surface Area (m^2). The specific type of infection being treated, such as treatment versus prophylaxis for PJP, is also a factor in determining the required dose.

Q: Is it true that I should avoid sun exposure while taking Бактрим?

A: Official labeling for this medication lists photosensitivity (increased skin sensitivity to sunlight) as a possible adverse reaction. This reaction is tied to an increased risk of severe sunburn or rash.

Q: Can men and women use Бактрим for the same types of infections?

A: The official approved uses for this medication, such as for urinary tract infections or certain types of pneumonia, are generally listed without differentiation based on patient sex.

Q: Does Бактрим affect the effectiveness of birth control pills?

A: Official interaction data indicates that the sulfamethoxazole component of this medication may reduce the effectiveness of certain estrogen-containing oral contraceptives. This effect occurs through the sulfamethoxazole component interfering with estrogen metabolism.

Q: How long after finishing the prescription does Бактрим stay in my system?

A: Regulatory information on the drug's properties states that the mean serum half-lives are approximately 10 hours for sulfamethoxazole and 8 to 10 hours for trimethoprim. The half-life is the time it takes for half of the drug to be eliminated from the body.

Q: Are there specific food restrictions or things I should avoid eating while on Бактрим?

A: Official regulatory labels typically do not list specific food prohibitions that must be avoided. However, product information generally states that the oral dose may be taken with or soon after food, which can help reduce the possibility of stomach upset.

Q: Does using Бактрим for a long time require any special monitoring or blood tests?

A: Official documentation notes that patients receiving this medication, particularly those with existing folate depletion or the elderly, should be monitored for signs of hematologic toxicity. This type of monitoring typically involves checking for changes in blood cell counts.

Q: Can Бактрим cause a change in my sense of taste?

A: Yes, regulatory-derived information lists a taste disorder, known medically as dysgeusia, as a less common side effect that has been reported in association with this medication.

Q: Why do some people report feeling dizzy or lightheaded after taking Бактрим?

A: Official safety data reports that vertigo, or dizziness, is listed as a possible side effect of this medication. This sensation of feeling dizzy or lightheaded is a known adverse reaction.

Q: Is there a higher chance of getting a yeast infection (thrush) after taking Бактрим?

A: Official regulatory labeling contains a general precaution that the overgrowth of non-susceptible organisms, including fungi, may occur during therapy. The potential for overgrowth of non-susceptible organisms is a general consideration during therapy with this type of medication.

Q: Does Бактрим affect the results of certain laboratory tests?

A: Yes, the trimethoprim component of this medicine may interfere with certain laboratory assays. Specifically, it can affect the test for serum creatinine (used to measure kidney function) and the assay for plasma methotrexate levels.

Advertisements

How should Бактрим be stored and disposed of?

Storage and Disposal Instructions for Bactrim (Co-trimoxazole)

Official regulatory guidelines mandate specific conditions to maintain the stability and quality of Bactrim (Sulfamethoxazole and Trimethoprim).


Storage Conditions

Dosage Form Temperature Requirement Protection Handling Restriction
Tablets/Suspension Controlled Room Temperature (20 C to 25 C) Store in a tight, light-resistant container Do not freeze the oral suspension
Injection Solution 15 C to 25 C Protect from light Use diluted solution within 6 hours

All forms must be stored out of the reach and sight of children.

Disposal

Expired or unused medicine must not be disposed of in household waste or flushed down the toilet. Patients should consult a pharmacist for instructions on proper disposal, following official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Бактрим found in:

A-Z Index: